The thesis

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company with 18.9% YoY revenue growth and a 9036.0% gross margin. The company's conviction score is 0/100, indicating a dormant state, despite an analyst consensus rating of BUY. The stark contrast between the conviction score and analyst rating makes the setup interesting. Aurinia's net margin is 10084.0%, indicating significant profitability.

Why now

The current macro context, with elevated energy prices and bond yields driving expectations of tighter monetary policy, may impact consumer discretionary spending, but biotech companies like Aurinia Pharmaceuticals may be insulated due to the essential nature of their products. The company's strong revenue growth and high margins make it an attractive investment opportunity in a potentially challenging macroeconomic environment.

What to watch

Investors should watch Aurinia's revenue growth over the next quarter to confirm whether the 18.9% YoY growth rate is sustainable. The company's ability to maintain its high gross margin will also be a key indicator of its continued profitability.

Key risks

The DCF intrinsic value of $-45 indicates significant valuation risk. Execution risk is also present, as the company's high margins and revenue growth may not be sustainable if it fails to continue innovating and commercializing therapies effectively.

Theme exposure